Not So Fast: Trump Team Paints US FDA Review Times As Too Slow
Executive Summary
New ‘statement of policy’ directs US FDA to publish charts of its approval timeliness – using an outdated 180-day benchmark to make its approval speed look worse.
You may also be interested in...
US FDA’s Unapproved Drugs Initiative Comes Back To Life, With New Enforcement Guidance On Its Way
Longstanding compliance policy program aimed at getting marketed but unapproved drugs through the NDA/ANDA pathway is reinstated because its termination by the Trump Administration was ‘legally and factually inaccurate’; some experts want FDA to consider program’s impact on drug pricing as it re-establishes the initiative.
FDA Chief Counsel Stacy Cline Amin Guided Agency Through COVID-19 EUAs And Guidances
Amin leaves after two-year stint, but Trump administration chaos continues as HHS names a different replacement chief counsel than FDA did earlier in the day. James Lawrence is tapped to be FDA's top lawyer and will presumably help speed a number of regulatory changes at the agency.
Some Long-Standing FDA Regs Face Mandatory Review Or Rescission Under New HHS Rule
Among those judged eligible are FDA rules governing adverse event reporting and the Unique Device Identification System.